Company: HRTX
Filing Date: 2025-09-19
Form Type: DEF 14A
Source: 0001193125-25-209064
Chunk: 12

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-19
Form: DEF 14A
Chunk 12
---
 in person or represented by proxy. To approve Proposal 1, holders of a majority of the votes cast on the matter must vote FOR the proposal. Only FOR and AGAINST votes will affect the outcome. Abstentions and broker non-votes will have no effect on the voting of Proposal 1.

Proposal 1 is not a routine matter. Therefore, if your shares are held by your bank, broker or other nominee in street name and you do not vote your shares, your bank, broker or other nominee may not vote your shares on Proposal 1.

The Board of Directors recommends a vote “FOR” the Notes Stock Issuance, including an amount above 19.99% of the number of shares of the Company’s Common Stock issued and outstanding prior to such issuance.

<div align='center'>11

PROPOSAL 2 - APPROVAL OF SHARE ISSUANCES UNDER SERIES A CONVERTIBLE PREFERRED STOCK</div>

Under the terms of a Securities Purchase Agreement, dated as of August 8, 2025 (the “Purchase Agreement”), the Company issued and sold (i) 13,225,227 unregistered shares of Common Stock at a purchase price of $1.50 per share and (ii) 524,141 unregistered shares of Series A Convertible Preferred Stock, which shall automatically convert upon receipt of the requisite votes of the Company’s stockholders required to approve the issuance of the Common Stock to be issued upon conversion of the Series A Convertible Preferred Stock (the “Series A Preferred StockholderApproval”) into 5,241,410 shares of Common Stock, at a conversion price of $1.50 per share (stated value of $15.00 per share), subject to appropriate adjustments in the event of a stock split, stock dividend, combination or other recapitalization affecting the Common Stock, for an aggregate investment amount of approximately $27.7 million, pursuant to exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D under the Securities Act. The Series A Convertible Preferred Stock will not be convertible into Common Stock until receipt of the Series A Preferred Stockholder Approval. Holders of the Series A Convertible Preferred Stock are entitled to dividends on an as-if converted basis in the same form as any dividends actually paid on shares of Common Stock or other securities of the Company. The shares of Series A Convertible Preferred Stock are convertible into shares of Common Stock at the conversion price in effect at the time of conversion, except that